With Sigma-Aldrich Corp. offering a purchase price
of $350 million to be financed through a combination of cash on hand and credit facilities, BioReliance Corp., a provider of global biopharmaceutical testing
services, has agreed to be acquired, with majority owner Avista Capital Partners giving the nod.
University of California, San Diego
(UCSD) recently announced that it has published data that validates RainDance Technology Inc.’s approach for detecting low-prevalence somatic mutations in
heterogeneous tumor samples.
With market pressures from generic drug manufacturers at an all-time
high, firms have turned to what’s known as “pay for delay,” a stalling tactic employed by originator pharmaceutical manufacturers to maintain market share
after a pharmaceutical patent has expired or has been found to be invalid in court.
Policy, like medical decisions, should be
based on evidence, not magic. Evidence to support policy should not be selected from a menu; policy should be derived from evidence. In 2012, we need to get
Have a seat and pass the mashed potatoes,
y’all: It’s time for a chat about celebrity chef and Food Network television host Paula Deen and the brouhaha surrounding her recent announcement that she
suffers from type 2 diabetes, the most common form of the disease whose primary cause is obesity.